Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Endocrine. 2014 Aug 17;49(1):231–241. doi: 10.1007/s12020-014-0383-y

Figure 4.

Figure 4

A. GH tumor response to somatostatin analogues (SSA). SG tumors were significantly less likely to be controlled with SSA compared to DG (p=0.028) B. GH adenoma subtypes and response to GH receptor antagonist, pegvisomant (PEG). The remission rates in response to PEG do not depend on tumor type (p=0.30)